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Context: The prevalence of diabetes mellitus (DM) in patients with primary aldosteronism (PA) 
is higher than in those with essential hypertension and the general population. Although DM is 
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a common major risk factor for cardio-cerebrovascular (CCV) diseases and renal complications, 
details of its effects in PA have not been demonstrated.
Objective: The aim of this study was to determine the effects of coexistent DM on the risk of 
CCV events and progression of renal complications in PA patients.
Design: A multi-institutional, cross-sectional study was conducted.
Patients and Methods: PA patients experienced between January 2006 and October 2016 and 
with available data of CCV events and DM were enrolled from the Japan PA registry of the 
Japan Primary Aldosteronism Study/Japan Rare Intractable Adrenal Diseases Study (n = 2524). 
CCV events and renal complications were compared between a DM group and a non-DM group 
by logistic and liner-regression analysis.
Results: DM significantly increased the odds ratio (OR) of CCV events (OR 1.59, 95% CI: 1.05-
2.41) and that of proteinuria (OR 2.25, 95% CI: 1.59-3.16). DM correlated significantly with 
declines in estimated glomerular filtration rate (β = .05, P = .02).
Conclusions: This the first report to demonstrate the presence of DM as an independent risk factor for 
CCV events and renal complications, even in PA patients. Management of DM should be considered in 
addition to the specific treatment of PA. (J Clin Endocrinol Metab 105: e2531–e2539, 2020)
Freeform/Key Words:  primary aldosteronism, diabetes mellitus, cardio-cerebrovascular events, 
proteinuria, eGFR
P rimary aldosteronism (PA) is a major cause of sec-ondary hypertension that affects 3.2% to 12.7% 
of hypertensive patients (1). PA patients are at higher 
risks of cardio-cerebrovascular (CCV) events compared 
to those with essential hypertension (EH), and the in-
creased risk is mainly due to excess aldosterone, which 
induces not only a rise in blood pressure but also dir-
ectly damages the myocardium and arterial walls (2, 3). 
Moreover, persistent exposure to excessive aldosterone 
is known to cause renal fibrosis and vasculopathies (4, 
5). This explains the high urinary albumin excretion 
rate in PA patients compared with EH patients (6). On 
the other hand, in patients with diabetes mellitus (DM), 
the risks of CCV events and proteinuria are high be-
cause of hyperglycemia (7).
The prevalence of DM in PA patients is 8.2% to 
23.0% (8-10) and is higher than in EH patients and 
the general population (11). Though both DM and 
PA play important roles in the progression of CCV 
diseases and renal complications, the relationship be-
tween DM and these diseases in PA patients has not 
been evaluated.
The aim of this study was to determine whether DM 
co-pathology in PA patients increases the risk of CCV 
events and progression of renal complications.
Methods
Study design
This retrospective cross-sectional study was conducted 
as part of the Japan Primary Aldosteronism Study/Japan 
Rare Intractable Adrenal Diseases Study (JPAS/JRAS) study 
including 30 referral centers. Patients with PA who were 
diagnosed and underwent adrenal vein sampling (AVS) from 
January 2006 to February 2018 were enrolled in this study. 
Patients eligible for JPAS were men and women age 20 to 
90 years. Patients deemed unsuitable by the investigators were 
excluded. The clinical characteristics, biochemical findings, and 
AVS results were collected electronically using the web registry 
system. System construction, data security, and maintenance of 
the registered data were outsourced to the EPS Corporation.
The study was conducted using a data set valid as of 
February 2018. Only patients with data available on clinical 
course and biochemistry laboratory test results, especially 
those related to DM and medical history of CCV events, were 
included. We excluded patients with suspected autonomous 
cortisol secretion, defined by serum cortisol levels greater than 
3 µg/dL after 1 mg dexamethasone.
We defined DM as glycated hemoglobin greater than or 
equal to 6.5% (National Glycohemoglobin Standardization 
Program), or treatment with medications or dietary and exer-
cise therapy specific for DM. Glycated hemoglobin greater 
than or equal to 6.5% is considered to represent DM ac-
cording to the American Diabetes Association (12) and the 
Japan Diabetes Society (13). CCV events were defined as 
myocardial infarction, heart failure (required hospitalization 
for treatment), cerebral infarction, and cerebral hemorrhage. 
Proteinuria was defined as +, 2+, and 3+ protein on urinalyses.
Diagnosis of primary aldosteronism
The diagnosis of PA was based on the criteria defined by the 
Japan Endocrine Society (14) and Japan Society of Hypertension 
(15). PA was diagnosed by positive case detection with a ratio 
of plasma aldosterone concentration (PAC) (measured in ng/
dL) to plasma renin activity (PRA) (measured in ng/mL/h) of 
greater than 20 and at least 1 positive result of 4 confirmatory 
tests, including the captopril-challenge test, the saline-infusion 
test, the furosemide-upright test, and the oral salt-loading test. 
Antihypertensive medications were usually changed to calcium 
channel blockers and/or α-adrenergic blockers, as appropriate, 
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Hormone assays
PAC and PRA were measured by commercially available 
kits. PAC was determined by radioimmunoassay in 27 cen-
ters and chemiluminescent enzyme immunoassay in 3 centers. 
PRA was determined by radioimmunoassay in 20 centers and 
EIA in 9 centers. Plasma active renin concentration was meas-
ured by chemiluminescent enzyme immunoassay in one center 
and the value was used for analysis by converting to PRA.
Statistical analysis
Data were expressed as median values (first and third quar-
tiles). Differences between parameters of 2 groups were com-
pared by the Wilcoxon test for continuous variables and by 
chi-square test for categorical variables. Significant variables 
were included in a multivariable logistic regression model to 
determine the independent risk factors associated with CCV 
events and proteinuria. Multiple regression analysis was used 
for estimated glomerular filtration rate (eGFR). Statistical sig-
nificance was defined as a significance level of P less than .05. 
All statistical analyses were performed using JMP Pro soft-
ware for Window (ver. 14, SAS Institute).
Results
Patients
Patients with PA with available data on CCV events 
and DM (n = 2524, men, 47.5%) were enrolled in 
this study. Table  1 summarizes the clinical character-
istics of these patients. The median age was 53  years 
(range, 45-62  years), median body mass index (BMI) 
was 24.4 kg/m2 (range, 21.9-27.3 kg/m2), median sys-
tolic blood pressure (SBP) was 140  mm  Hg (range, 
129-152  mm  Hg), median diastolic blood pressure 
(DBP) was 86 mm Hg (range, 78-95 mm Hg), median 
duration of hypertension at the time of PA diagnosis 
was 5  years (range, 2-12  years), the mean number of 
antihypertensive classes was 1.0 (range, 1.0-1.0), median 
PAC was 17.8 ng/dL (range, 12.6-27.9 ng/dL), median 
PRA was 0.3 ng/mL/h (range, 0.2-0.5 ng/mL/h), and the 
median plasma aldosterone/plasma renin activity ratio 
was 55.8 (range, 32.8-114.6). A unilateral subtype was 
identified in 621 patients (30.3%) and bilateral subtype 
in 1426 patients. Of the total, 26.9% had dyslipidemia 
and 41.4% had hypokalemia. Of the 2524 PA patients, 
389 (15.4%) had DM, and 182 (7.2%) CCV events 
were recorded in these patients, with cerebral infarction 
being the most common. The incidence of proteinuria 
was 10.7%. The median eGFR was 77.9 mL/min/1.73 
m2 (range, 66.4-91.4 mL/min/1.73 m2).
Comparison of clinical characteristic between the 
diabetes mellitus group and the non–diabetes 
mellitus group in primary aldosteronism patients
Table  2 shows the differences between PA patients 
of the DM group and the non-DM group. As stated 
earlier, 389 (15.4%) of the 2524 PA patients had DM. 
Compared with the non-DM group, the DM group in-
cluded significantly more older (59 vs 53 years, P < .01), 
obese (BMI, 25.9 vs 24.1  kg/m2, P < .01), smoking 
(44.3 vs 34.3%, P < .01) men (60.8 vs 45.2%, P < .01) 
with a longer duration of hypertension (10 vs 5 years, 
P < .01), taking more antihypertensive drugs (1.0 [1.0-
2.0] vs 1.0 [1.0-1.0], P < .01), and a higher incidence 
of dyslipidemia (45.0 vs 23.6%, P < .01). There were 
no significant differences in PAC, PRA, and incidence 
of hypokalemia between the 2 groups. PA subtype clas-
sified by AVS was similar (unilateral, 29.8 vs 30.4%, 
P = .84) in both groups.




Age, y 53 (45-62)
Body mass index, kg/m2 24.4 (21.9-27.3)
Systolic blood pressure, mm Hg 140 (129-152)
Diastolic blood pressure, mm Hg 86 (78-95)
Duration of hypertension, y 5 (2-12)
No. of antihypertensive drugs 1.0 (1.0-1.0)
Plasma aldosterone, ng/dL 17.8 (12.6-27.9)
Plasma renin activity, ng/mL/h 0.3 (0.2-0.5)
ARR, ng/dL/ng/mL/h 55.8 (32.8-114.6)
Unilateral subtype 30.3%
Hypokalemia 41.4%
Serum potassium, mEq/L 3.8 (3.4-4.0)
Diabetes mellitus 15.4%
FBS, mg/dL 98 (91-109)
HbA1c NGSP, % 5.6 (5.3-6.0)
Dyslipidemia 26.9%
Current or past smoking 35.8%
Current or past drinking 53.7%
CCV events 7.2%
 Myocardial infarction 0.9%
 Cerebral hemorrhage 2.4%
 Cerebral infarction 4.1%
 Heart failure 0.5%
Proteinuria 12.1%
eGFR, mL/min/1.73 m2 77.9 (66.4-91.4)
The values in parentheses are median (first and third quartiles).
Unilateral subtype was evaluated by adrenal vein sampling results 
with adrenocorticotropic hormone (cosyntropin) stimulation if cannu-
lation was successful (selectivity index > 5). The selectivity index was 
defined as the cortisol concentration in the adrenal vein relative to 
that in the inferior vena cava. The diagnosis of unilateral PA subtype 
was defined as a lateralization index greater than 4. The lateralization 
index was calculated by that on the nondominant side. Hypokalemia 
represented serum potassium less than 3.5 mEq/L at the diagnosis of 
PA or taking potassium supplementation. Oral potassium was sup-
plemented if hypokalemia was present. eGFR was obtained using the 
following equation: eGFR (mL/min/1.73 m2) = 194 × serum creatinine 
(–1.094) × age (–0.287) × 0.739 (for women). Proteinuria was defined 
as +, 2+, and 3+ protein on urinalysis.
Abbreviations: ARR, plasma aldosterone/plasma renin activity ratio; 
CCV events, cardio-cerebrovascular events; eGFR, estimated glomeru-
lar filtration rate; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; 
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The rate of CCV events was significantly higher in 
the DM group (13.9 vs 6.0%, P < .01), especially for 
myocardial infarction (2.6 vs 0.6%, P < .01), cerebral 
infarction (8.2 vs 3.4%, P < .01), and heart failure (1.5 
vs 0.3%, P < .01). With regard to renal complications, 
the incidence of proteinuria was significantly higher 
(24.8 vs 9.6%, P < .01) and eGFR was significantly 
lower (76.8 vs 78.4  mL/min/1.73 m2, P < .05) in the 
DM group than in the non-DM group.
Logistic regression analysis for cerebro-
cardiovascular events and renal complications
Logistic regression analysis was performed to in-
vestigate the relation of sex, age, BMI, SBP, duration 
of hypertension, dyslipidemia, smoking, and drinking 
with CCV events and renal complications. In addition 
to male sex, older age, long duration of hypertension, 
dyslipidemia, and smoking, DM (odds ratio [OR] 1.59, 
95% CI: 1.05-2.41) significantly increased, whereas 
drinking decreased the OR of CCV events (Table  3). 
With regard to renal complications, DM (OR 2.25, 95% 
CI: 1.59-3.16), in addition to other parameters, such as 
male sex, obesity, high SBP, and long duration of hyper-
tension, significantly increased the OR of proteinuria 
(Table  4). Multiple regression analysis identified DM 
(β = .05, P = .02), male sex, old age, and long duration 
of hypertension to be significant correlates with the de-
cline in eGFR (Table 5).
In patients of the nonproteinuria group, eGFR cor-
related significantly with DM (β = .09, P < .01), whereas 
no such correlation was found in the proteinuria group 
(β = –.01, P = .85).
Discussion
PA and DM are both well-known important risk fac-
tors for CCV events and renal complications. In this 
study, we demonstrated that DM was an independent 
risk factor for CCV events and renal complications in 
PA patients. With regards to PA subtypes, the incidences 
of CCV events and proteinuria both in unilateral and 
bilateral subtypes with DM were higher compared 
with those without DM, respectively (CCV events in 
unilateral; DM group vs non-DM group 21.3% vs 
8.2%, P < .01, proteinuria in unilateral; DM group vs 
non-DM group 36.7% vs 17.3%, P < .01, CCV events 
in bilateral; DM group vs non-DM group 10.0% vs 
4.8%, P < .01, proteinuria in bilateral; DM group vs 
Table 2. Comparison of clinical characteristics of diabetes mellitus and non–diabetes mellitus groups of 
primary aldosteronism patients
DM (n = 389) Non-DM (n = 2135) P
Sex, male 60.7% 45.2% < .01
Age, y 59 (51-65) 53 (44-61) < .01
Body mass index, kg/m2 25.9 (23.1-29.2) 24.1 (21.7-26.9) < .01
Systolic blood pressure, mm Hg 141 (129-154) 140 (129-152) .19
Diastolic blood pressure, mm Hg 85 (76-93) 87 (78-95) < .01
Duration of hypertension, y 10 (2-19) 5 (2-11) < .01
No. of antihypertensive drugs 1.0 (1.0-2.0) 1.0 (1.0-1.0) < .01
Plasma aldosterone, ng/dL 17.2 (12.5-26.8) 17.9 (12.6-28.3) .24
Plasma renin activity, ng/mL/h 0.3 (0.2-0.5) 0.3 (0.2-0.5) .38
ARR, ng/dL/ng/mL/h 52.6 (32.4-97.7) 56.3 (32.8-118.0) .16
Unilateral subtype 29.8% 30.4% .84
Hypokalemia 39.8% 41.7% .51
Serum potassium, mEq/L 3.8 (3.4-4.1) 3.8 (3.4-4.0) .08
FBS, mg/dL 128 (110-154) 96 (90-104) < .01
HbA1c NGSP, % 6.8 (6.4-7.8) 5.5 (5.3-5.8) < .01
Dyslipidemia 45.0% 23.6% < .01
Current or past smoking 44.3% 34.3% < .01
Current or past drinking 51.0% 54.2% .28
CCV events 13.9% 6.0% < .01
 Myocardial infarction 2.6% 0.6% < .01
 Cerebral hemorrhage 3.1% 2.3% .35
 Cerebral infarction 8.2% 3.4% < .01
 Heart failure 1.5% 0.3% < .01
Proteinuria 24.8% 9.6% < .01
eGFR, mL/min/1.73 m2 76.8 (63.5-91.0) 78.4 (66.9-91.5) < .05
The values in parentheses are median (first and third quartiles). P values for differences between the DM and non-DM group (sex, current or past 
smoking, current or past drinking, unilateral subtype, hypokalemia, dyslipidemia, proteinuria, and CCV events) by the chi-square test, for others by 
the Wilcoxon test.
Abbreviations: ARR, plasma aldosterone/plasma renin activity ratio; CCV events, cardio-cerebrovascular events; DM, diabetes mellitus; eGFR, esti-
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non-DM group 18.7% vs 6.4%, P < .01). These results 
suggest that DM itself plays an important role in the 
progression of CCV diseases and proteinuria in spite 
of PA subtypes.
A recent meta-analysis has shown that PA patients 
are at significantly higher risk of CCV events com-
pared with EH patients (stroke OR 2.58 [95% CI: 
1.93-3.45], coronary heart disease OR 1.77 [95% CI: 
1.10-2.83], heart failure OR 2.05 (95% CI: 1.11-3.78]) 
(2). Moreover, PA patients have a higher urine albumin 
excretion rate than EH patients (6). It is known that 
adrenalectomy and treatment with mineralocorticoid 
receptor antagonists are effective treatments that reduce 
CCV event risk (16, 17) and proteinuria (18) in PA pa-
tients. Therefore, early diagnosis and treatment of PA 
should prevent these risks.
The prevalence of DM is higher in PA than EH and 
the general population (11). In the present study, the 
prevalence of DM in PA patients was 15.4%, which is 
similar to those of previous studies (range, 8.2-23.0%) 
(8-10). In the former JPAS study whose patients with 
autonomous cortisol secretion were included, the 
Table 3. Risk factors for cardio-cerebrovascular events
Variable
Univariate analysis Multivariable analysis
OR (95% CI) P OR (95% CI) P
Diabetes mellitus 2.53 (1.80-3.55) < .01 1.59 (1.05-2.41) .03
Sex, male 2.09 (1.53-2.86) < .01 1.98 (1.29-3.04) < .01
Age, +10 y 1.70 (1.47-1.98) < .01 1.40 (1.15-1.71) < .01
Body mass index, +5 kg/m2 1.09 (0.91-1.31) .33 0.96 (0.76-1.22) .74
Systolic blood pressure, +10 mm Hg 1.02 (0.94-1.11) .56 1.03 (0.94-1.14) .54
Duration of hypertension, +5 y 1.33 (1.24-1.43) < .01 1.21 (1.11-1.32) < .01
Dyslipidemia 2.34 (1.72-3.18) < .01 1.61 (1.11-2.34) .01
Current or past smoking 1.73 (1.25-2.39) < .01 1.58 (1.06-2.34) .02
Current or past drinking 0.71 (0.52-0.99) .04 0.50 (0.34-0.74) < .01
Abbreviation: OR, odds ratio.
Table 4. Risk factors for proteinuria
Variable 
Univariate analysis Multivariable analysis
OR (95% CI) P OR (95% CI) P
Diabetes mellitus 3.09 (2.34-4.09) < .01 2.25 (1.59-3.16) < .01
Sex, male 3.26 (2.47-4.31) < .01 2.73 (1.91-3.92) < .01
Age, +10 y 1.20 (1.07-1.34) < .01 1.02 (0.88-1.20) .77
Body mass index, +5 kg/m2 1.64 (1.42-1.89) < .01 1.31 (1.10-1.57) < .01
Systolic blood pressure, +10 mm Hg 1.20 (1.13-1.29) < .01 1.20 (1.11-1.30) < .01
Duration of hypertension, +5 y 1.28 (1.21-1.36) < .01 1.24 (1.15-1.34) < .01
Dyslipidemia 1.53 (1.17-2.00) < .01 1.04 (0.75-1.43) .83
Current or past smoking 1.51 (1.15-1.98) < .01 0.97 (0.70-1.34) .87
Current or past drinking 1.23 (0.94-1.62) .13 0.92 (0.67-1.28) .63
Abbreviation: OR, odds ratio.
Table 5. Results of multiple linear regression analysis for the association of estimated glomerular filtration 
rate with various factors
Variable
Univariate analysis Multivariable analysis
β P β P
Diabetes mellitus –.05 .01 .05 .02
Sex, male –.12 < .01 –0.12 < .01
Age –.43 < .01 –0.41 < .01
Body mass index –.01 .77 –0.03 .18
Systolic blood pressure –.03 .12 –0.03 .21
Duration of hypertension –.24 < .01 –0.07 < .01
Dyslipidemia –.08 < .01 –0.00004 1.00
Current or past smoking –.03 .11 –0.01 .55
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prevalence of DM in PA patients was higher than in 
the present study (21.6% vs 15.4%) (19). Hypokalemia 
and hyperaldosteronemia are known for the risk fac-
tors of DM in PA patients. However, there were no sig-
nificant differences in the incidence of hypokalemia and 
PAC levels between the DM group and the non-DM 
group in our study. The same results have been reported 
in previous studies (8, 20). These results suggested that 
aging, high BMI, and lifestyle habits (21) have a larger 
contribution to the onset of glucose intolerance com-
pared with hypokalemia and hyperaldosteronemia.
Current or past drinking decreased the OR for CCV 
events (OR 0.50, 95% CI: 0.34-0.74) in our study. 
Although we do not have any data about alcohol con-
sumption, Saito et al (22) reported that the association 
of alcohol consumption with mortality due to heart 
disease and cerebrovascular disease was examined in 
the Japanese population. Light to moderate alcohol con-
sumption (men < 300 g/week and women < 150 g/week) 
in drinkers was the lower risk of CCV events compared 
with nondrinkers. About 70% of men drank less than 
300 g/week and more than 90% of women drank less 
than 150 g/week. The authors concluded that alcohol 
intake showed J-shaped or U-shaped associations with 
the risk of CCV events in Japanese population.
The clinical course of diabetic nephropathy is clas-
sified into 5 stages: stage 1 hyperfiltration, stage 2 
the silent stage, stage 3 microalbuminuria, stage 4 
macroalbuminuria, and stage 5 uremia (23). In our 
study, we showed that DM correlated positively with a 
decrease in eGFR in PA patients. The reason for this cor-
relation was that 75% of the participating patients had 
stage 1 to 3 diabetic nephropathy (eGFR; 76.8 [63.5-
91.0] mL/min/1.73 m2, proteinuria; 24.8%). When our 
patients were divided into 2 groups—the nonproteinuria 
group and proteinuria group—our analysis showed no 
correlation between DM and eGFR in the proteinuria 
group, whereas DM and eGFR correlated significantly 
with each other in the nonproteinuria group. One limi-
tation of this study was its retrospective cross-sectional 
design. Further studies are needed to determine the ef-
fect of long-term treatment of PA patients on glucose 
intolerance, DM, and incidence of CCV events.
In conclusion, this is the first report to demonstrate 
the presence of DM as an independent risk factor for 
CCV events and renal complications even in PA pa-
tients. Management of DM should be considered in 
addition to the specific treatment of PA.
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